# A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)

> **NCT02145468** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 3503 (actual)

## Conditions studied

- Acute Coronary Syndrome

## Interventions

- **DRUG:** Losmapimod 7.5 mg twice daily
- **DRUG:** Placebo twice daily
- **DRUG:** Standard therapy

## Key facts

- **NCT ID:** NCT02145468
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-03
- **Primary completion:** 2015-12-14
- **Final completion:** 2015-12-14
- **Target enrollment:** 3503 (ACTUAL)
- **Last updated:** 2017-06-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02145468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02145468, "A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02145468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*